Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[99mTc]HYNIC-siRNA 1489
- Development stage
- Preclinical
- Lead developer
- Harbin Medical University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
[99mTc]HYNIC-siRNA 1489 is a technetium-99m labeled small interfering RNA (siRNA) molecular imaging probe designed for single-photon emission computed tomography (SPECT) imaging of murine double minute 2 (MDM2) expression. MDM2 is an oncogene that plays a critical role in tumorigenesis, metastasis, and chemotherapy resistance by acting as a negative regulator of the p53 tumor suppressor. The probe consists of a specific siRNA sequence (siRNA 1489) targeting MDM2 mRNA, conjugated to the chelator hydrazinonicotinamide (HYNIC) and radiolabeled with technetium-99m ([99mTc]). Developed by researchers at Harbin Medical University, the probe is designed to evaluate MDM2 expression levels in vivo, potentially offering a non-invasive strategy for the early diagnosis and stratification of breast cancer and other MDM2-overexpressing malignancies.
- Other names
- 99mTc-HYNIC-siRNA 1489[99mTc]Tc-HYNIC-siRNA 1489
02
Targets
MDM2 (Mouse double minute 2 homolog)TP53 (Cellular Tumor Antigen p53 R175H)
Beyond the preview
Go deeper on [99mTc]HYNIC-siRNA 1489.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [99mTc]HYNIC-siRNA 1489.